Sector News

Generics set to undercut blockbusters from Merck, Novartis and BMS

January 17, 2017
Life sciences

Several blockbusters are set to take a nosedive this year as patent losses hit Novartis, Merck & Co., Bristol-Myers Squibb and other top pharma companies.

Dickson Data has compiled a list of major drugs losing their IP protection this year, and standing at the top is Novartis’ Sandostatin LAR with $1.6 billion in annual sales. Used to treat acromegaly and severe diarrhea and flushing associated with carcinoid syndrome, the drug will quickly face generic erosion from a slew of companies, including Teva, Sun Pharma, Sagent Pharmaceuticals and Wockhardt.

Behind Sandostatin LAR is Merck’s antibiotic Cubicin, a key prize in the New Jersey pharma giant’s $9.5 billion purchase of Cubist Pharmaceuticals back in 2014. The drug currently tallies $1.17 billion in sales, according to Dickson, and is set to face cheaper rivals from Hospira, Teva and Crane Pharma, FDA records show.

Merck faces another blockbuster loss, too: Its cholesterol med Vytorin, with $1.12 billion in sales, comes in fourth place, according to Dickson. Bristol-Myers’ HIV drug Reyataz stands in third place with $1.14 billion.

Branded drugs tend to lose 90% of their sales after multiple generics make it to market, according to the firm. The copycats are typically 80 to 85% cheaper than the branded originals.

Although not a blockbuster like others on the list, Eli Lilly’s ADHD med Strattera rounds out the top five drugs facing a patent expiration, Dickson found, with annual sales just shy of $700 million. Zydus, Aurobindo, Sun Pharma and Mylan are among the companies seeking to grab a piece of that drug’s annual haul.

Merck’s antibiotic Invanz and antifungal med Cancidas are also set to lose patent protection for the New Jersey pharma giant; all told, the drugmaker has four meds totaling $3.8 billion in sales—10% of its total haul—susceptible to generics this year.

By Eric Sagonowsky

Source: Fierce Pharma

Related News

June 13, 2021

Making drug-resistant bacteria susceptible to antibiotics

Life sciences

Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.

June 13, 2021

Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck

Life sciences

Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.

June 13, 2021

Beigene expands into cancer cell therapy with Shoreline pact

Life sciences

Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.

Send this to a friend